Literature DB >> 27643870

High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.

Y Arai1, T Kondo1, A Shigematsu2, J Tanaka3, S Takahashi4, T Kobayashi5, N Uchida6, Y Onishi7, J Ishikawa8, H Kanamori9, M Sawa10, A Yokota11, Y Kouzai12, M Takanashi13, T Ichinohe14, Y Atsuta15,16, S Mizuta17.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27643870     DOI： 10.1038/bmt.2016.242

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL.

Authors:  J Ooi; S Takahashi; A Tomonari; N Tsukada; T Konuma; S Kato; S Kasahara; A Sato; F Monma; F Nagamura; T Iseki; A Tojo; S Asano
Journal:  Bone Marrow Transplant       Date:  2008-10-27       Impact factor: 5.483

2.  Has MRD monitoring superseded other prognostic factors in adult ALL?

Authors:  Monika Brüggemann; Thorsten Raff; Michael Kneba
Journal:  Blood       Date:  2012-10-02       Impact factor: 22.113

Review 3.  Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.

Authors:  Michael S Mathisen; Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Elias Jabbour
Journal:  Leuk Lymphoma       Date:  2013-06-21

4.  Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  L Tucunduva; A Ruggeri; G Sanz; S Furst; G Socié; M Michallet; W Arcese; N Milpied; I Yakoub-Agha; W Linkesch; J Cornelissen; L Mannone; A P Iori; J-M Ribera; J Sanz; P Montesinos; D Purtill; M Labopin; E Gluckman; M Mohty; V Rocha
Journal:  Bone Marrow Transplant       Date:  2014-07       Impact factor: 5.483

5.  Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.

Authors:  José A Pérez-Simón; María Díez-Campelo; Rodrigo Martino; Salut Brunet; Alvaro Urbano; María D Caballero; Angel de León; David Valcárcel; Enric Carreras; María C del Cañizo; Jesús López-Fidalgo; Jordi Sierra; Jesús F San Miguel
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

6.  Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan.

Authors:  T Matsumura; M Kami; T Yamaguchi; K Yuji; E Kusumi; S Taniguchi; S Takahashi; M Okada; H Sakamaki; H Azuma; M Takanashi; H Kodo; S Kai; T Inoue-Nagamura; K Kato; S Kato
Journal:  Leukemia       Date:  2012-01-17       Impact factor: 11.528

7.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

Review 8.  Umbilical cord blood transplantation: the first 25 years and beyond.

Authors:  Karen K Ballen; Eliane Gluckman; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

Review 9.  High-dose cytarabine (HD araC) in the treatment of leukemias: a review.

Authors:  Nicholas D Reese; Gary J Schiller
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

10.  Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; Kazunari Aoki; June Takeda; Tadakazu Kondo; Tetsuya Eto; Shuichi Ota; Hisako Hashimoto; Takahiro Fukuda; Yukiyasu Ozawa; Yoshinobu Kanda; Chiaki Kato; Mineo Kurokawa; Koji Iwato; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Akiyoshi Takami
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.